Now showing items 1-9 of 9

    • FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study 

      Tedesco-Silva, H. [UNIFESP]; Lorber, M. I.; Foster, C. E.; Sollinger, H. W.; Mendez, R.; Carvalho, D. B.; Shapiro, R.; Rajagopalan, P. R.; Mayer, H.; Slade, J.; Kahan, B. D.; FTY720A2202 Clinical Study Grp (Wiley-Blackwell, 2009-09-01)
      This exploratory, multicenter, open-label study evaluated the efficacy and safety of FTY720, as a part of an immunosuppressive regimen, in combination with everolimus and steroids in de novo renal transplant recipients at ...

    • FTY720 and lung tumor development 

      Antunes Salinas, Natalia Regina [UNIFESP]; Oshima, Celina Tizuko Fujiyama [UNIFESP]; Cury, Patricia Maluf; Cordeiro, Jose Antonio; Bueno, Valquiria [UNIFESP] (Elsevier B.V., 2009-06-01)
      FTY720 has been shown to prevent cancer development in experimental models but there is no report whether this beneficial effect is associated with the time point of the drug administration. Lung adenoma was induced in ...

    • FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system 

      Pereira, Felipe Valença [UNIFESP]; Arruda, Denise Costa [UNIFESP]; Figueiredo, Carlos Rogerio [UNIFESP]; Massaoka, Mariana Hiromi [UNIFESP]; Matsuo, Alisson Leonardo [UNIFESP]; Bueno, Valquiria [UNIFESP]; Rodrigues, Elaine Guadelupe [UNIFESP] (Faculdade de Medicina / USP, 2013-07-01)
      OBJECTIVE: Available chemotherapy presents poor control over the development of metastatic melanoma. FTY720 is a compound already approved by the Food and Drug Administration for the treatment of patients with multiple ...

    • FTY720 versus mycophenolate mofetil in de novo renal transplantation: Six-month results of a double-blind study 

      Tedesco-Silva, Helio; Szakaly, Peter; Shoker, Ahmed; Sommerer, Claudia; Yoshimura, Norio; Schena, Francesco Paolo; Cremer, Malika; Hmissi, Abdel; Mayer, Hartmut; Lang, Philippe; FTY720 2218 Clinical Study Grp (Lippincott Williams & Wilkins, 2007-10-15)
      Background. FTY720 is a novel immunomodulator that was developed to produce optimal graft protection with improved safety and tolerability. Phase II studies have demonstrated the efficacy of FTY720 up to the doses of 2.5 ...

    • The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection 

      Commodaro, Alessandra Goncalves [UNIFESP]; Pedregosa, Juliana Figueredo [UNIFESP]; Peron, Jean Pierre; Brandao, Wesley; Rizzo, Luiz Vicente; Bueno, Valquiria [UNIFESP] (Hospital Clinicas, Univ São Paulo, 2012-01-01)
      OBJECTIVES: FTY720 modulates CD4(+)T cells by the augmentation of regulatory T cell activity, secretion of suppressive cytokines and suppression of IL-17 secretion by Th17 cells. To further understand the process of graft ...

    • Lung Tumor Development in the Presence of Sphingosine 1-phosphate Agonist FTY720 

      Salinas, Natalia Regina Antunes [UNIFESP]; Lopes, Camila Takao [UNIFESP]; Palma, Patricia V.; Oshima, Celina Tizuko Fujiyama [UNIFESP]; Bueno, Valquiria [UNIFESP] (Springer, 2009-12-01)
      Urethane is a chemical carcinogen which causes lung tumorigenesis in mice with similarities to human adenocarcinoma (AC). the sphingosine 1-phosphate agonist FTY720 administered to mice in doses above 5 mg/kg/day has been ...

    • Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients 

      Park, Sung In [UNIFESP]; Felipe, Claudia Rosso [UNIFESP]; Machado, Paula Goulart Pinheiro [UNIFESP]; Garcia, Riberto [UNIFESP]; Skerjanec, Andrej; Schmouder, Robert; Tedesco-Silva Junior, Hélio [UNIFESP]; Pestana, Jose Osmar Medina [UNIFESP] (Associação Brasileira de Divulgação Científica, 2005-05-01)
      FTY720 is a new and effective immunosuppressive agent, which produces peripheral blood lymphopenia through a lymphocyte homing effect. We investigated the relationship between the dose of FTY720 or blood concentration ...

    • Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation 

      Tedesco-Silva, Helio; Pescovitz, Mark D.; Cibrik, Diane; Rees, Michael A.; Mulgaonkar, Shamkant; Kahan, Barry D.; Gugliuzza, Kristene K.; Rajagopalan, P. R.; Esmeraldo, Ronaldo de M.; Lord, Helene; Salvadori, Maurizio; Slade, Jennifer M.; FTY720 Study Grp (Lippincott Williams & Wilkins, 2006-12-27)
      Background. Phase 11 trials of FTY720, a novel immunomodulator, have shown promise in preventing rejection with both standard and reduced cyclosporine exposure. This study was designed to confirm those findings.Methods. ...

    • Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi 

      Dominguez, Mariana Ribeiro [UNIFESP]; Ersching, Jonatan [UNIFESP]; Lemos, Ramon [UNIFESP]; Machado, Alexandre V.; Bruna-Romero, Oscar; Rodrigues, Mauricio Martins [UNIFESP]; Vasconcelos, Jose Ronnie Carvalho de [UNIFESP] (Elsevier B.V., 2012-04-16)
      T-cell mediated immune responses are critical for acquired immunity against infection by the intracellular protozoan parasite Trypanosoma cruzi. Despite its importance, it is currently unknown where protective T cells are ...